EIF4G3 as A Potential Drug Target and Biomarker for Diabetes and Cardiovascular Disease

Target Name: EIF4G3

NCBI ID: G8672

EIF4G3

EIF4G3 as A Potential Drug Target and Biomarker for Diabetes and Cardiovascular Disease

EIF4G3 (IF4G3_HUMAN) as a Drug Target and Biomarker: A Potential Target for the Treatment of Diabetes and Cardiovascular Disease

Abstract:

EIF4G3 (IF4G3_HUMAN), a gene that encodes the insulin-like growth factor 4 (IGF-4) receptor, has been identified as a potential drug target and biomarker for the treatment of diabetes and cardiovascular disease. IGF-4 is a critical signaling molecule that plays a crucial role in the growth and development of tissues, including muscles, bones, and organs. High levels of IGF-4 have been associated with an increased risk of several diseases, including diabetes and cardiovascular disease. This article discusses the potential mechanisms by which EIF4G3 can contribute to the development and progression of these diseases, as well as the ongoing research to develop EIF4G3 as a drug target and biomarker.

Introduction:

Diabetes and cardiovascular disease are major public health concerns that affect millions of people worldwide. The development and progression of these diseases are influenced by a complex interplay of genetic and environmental factors. One of the key factors that has been identified as a potential biomarker and drug target for these diseases is the insulin-like growth factor 4 (IGF-4) receptor. IGF-4 is a transmembrane protein that plays a critical role in the growth and development of tissues, including muscles, bones, and organs. High levels of IGF-4 have been associated with an increased risk of several diseases, including diabetes and cardiovascular disease.

EIF4G3 (IF4G3_HUMAN):

EIF4G3 is a gene that encodes the IGF-4 receptor. The IGF-4 receptor is a key transcription factor that regulates the expression of genes involved in cell growth, differentiation, and survival. EIF4G3 has been shown to play a role in the regulation of cellular processes, including cell growth, angiogenesis, and inflammation.

EIF4G3 has also been shown to be involved in the development and progression of several diseases, including diabetes and cardiovascular disease. For example, studies have shown that individuals with type 2 diabetes have lower levels of IGF-4 than those without the disease. Additionally, IGF-4 has been linked to the development of cardiovascular disease, including heart failure, coronary artery spasms, and stroke.

Drug Targeting:

The potential use of EIF4G3 as a drug target is based on its role in the regulation of cellular processes and its association with several diseases. One potential approach to drug targeting EIF4G3 is to use small molecules or antibodies that can modulate its activity. This can include inhibiting the activity of EIF4G3's downstream signaling pathways, such as the PI3K/Akt signaling pathway, which is involved in cell growth and survival.

Another potential approach to drug targeting EIF4G3 is to target its intracellular localization. IGF-4 is known to be expressed in a variety of tissues and cells, including pancreatic beta cells, muscle fibers, and blood vessels. By using antibodies or small molecules that specifically target EIF4G3, researchers may be able to reduce its levels in certain tissues and cells, which could potentially lead to therapeutic effects.

Biomarker Potential:

In addition to its potential as a drug target, EIF4G3 may also be a useful biomarker for the diagnosis and monitoring of diabetes and cardiovascular disease. The IGF-4 receptor has been shown to be involved in the regulation of cellular processes that are involved in the development of these diseases, including inflammation, fibrosis, and autophagy. Therefore, measuring the levels of IGF-4 in tissues or cells may be a useful diagnostic or predictive marker for

Protein Name: Eukaryotic Translation Initiation Factor 4 Gamma 3

Functions: Component of the protein complex eIF4F, which is involved in the recognition of the mRNA cap, ATP-dependent unwinding of 5'-terminal secondary structure and recruitment of mRNA to the ribosome (PubMed:9418880). Functional homolog of EIF4G1 (PubMed:9418880)

The "EIF4G3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF4G3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets